Overview

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
The trial will consist of a single treatment group enrolling adult subjects with CF on background therapy with KALYDECO®. Approximately 16 subjects will be enrolled.
Phase:
Phase 1
Details
Lead Sponsor:
Proteostasis Therapeutics, Inc.